drugset / Trial / NCT07193966
NG2 and DLL3 CAR-T Cells Targeting Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2028-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NG2 and DLL3 CAR-T cells | Cell therapy | — | Intravenous |